Archives of Sexual Behavior

, Volume 25, Issue 1, pp 1–16 | Cite as

Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction

  • Klaus Mann
  • Thomas Klingler
  • Susanne Noe
  • Joachim Röschke
  • Stefan Müller
  • Otto Benkert


The therapeutic effect of the α2-antagonist yohimbine in erectile dysfunction was studied in a double-blind placebo-controlled design. Thirty-one male patients underwent extensive clinical, urological, and psychiatric diagnosis and were dichotomically classified into an organic and a nonorganic subgroup. Following a 1-week placebo run-in period, patients were randomly assigned to a placebo or a verum group (yohimbine 15 mg daily) for a treatment period of 7 weeks. The Clinical Global Impression (CGI) scale was used as the primary efficacy parameter. Additionally, nocturnal penile tumescence and rigidity (NPTR) were measured. Global assessment of erectile function applying the CGI scale revealed, beyond a placebo effect in both organic and nonorganic patients, a therapeutic effect in the subgroup of nonorganic patients, with a significantly greater improvement in the yohimbine group compared to the placebo group. No superiority of yohimbine compared to placebo was found in the organic patients. These findings on the subjective level had no correlate in the NPTR recordings. The NPTR parameters were unchanged under yohimbine treatment in both the nonorganic and organic subgroup. No interrelation was found between subjective improvement and NPTR alterations. Polysomnographic control of the NPTR registrations ensured that the duration of REM sleep under treatment was not influenced.

Key Words

yohimbine erectile dysfunction clinical global impression nocturnal penile tumescence and rigidity sleep EEG 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association (1987).Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., rev., APA, Washington, DC.Google Scholar
  2. Benkert, O., Maier, W., and Holsboer, F. (1985). Multiaxial classification of male sexual dysfunction.Br. J. Psychiat. 146: 628–632.CrossRefGoogle Scholar
  3. Brindley, G. S. (1986). Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis.Br. J. Pharmacol. 87: 495–500.PubMedGoogle Scholar
  4. Clark, J. T., Smith, E. R., and Davidson, J. M. (1984). Enhancement of sexual motivation in male rats by yohimbine.Science 225: 847–848.PubMedGoogle Scholar
  5. Clark, J. T., Smith, E. R., and Davidson, J. M. (1985). Evidence for the modulation of sexual behavior by α-adrenoceptors in male rats.Neuroendocrinology 41: 36–43.PubMedGoogle Scholar
  6. Condra, M., Morales A., Surridge, D. H., Owen, J. A., Marshall, P., and Fenemore, J. (1986). The unreliability of nocturnal penile tumescence recordings as an outcome measurement in the treatment of organic impotence.J. Urol. 135: 280–282.PubMedGoogle Scholar
  7. Goldberg, M. R., and Robertson, D. (1983). Yohimbine: A pharmacological probe for study of the α2-adrenoreceptor.Pharmacol. Rev. 35: 143–180.PubMedGoogle Scholar
  8. Guy, W. (1976).ECDEU Assessment Manual for Psychopharmacology, Revised, DHEW Publication (ADM), National Institute for Mental Health, Rockville, MD.Google Scholar
  9. Krause, J., Herth, T., Maier, W., Steiger, A., Schöneich, S., and Benkert, O. (1991). An interdisciplinary study towards a multiaxial classification of male sexual dysfunction.Acta Psychiat. Scand. 84: 130–136.PubMedGoogle Scholar
  10. Lancet. (1986). Yohimbine: Time for resurrection?Lancet 2: 1194–1195.Google Scholar
  11. Meisler, A. W., and Carey, M. P. (1990). A critical review of nocturnal penile tumescence monitoring in the diagnosis of erectile dysfunction.J. Nerv. Men. Dis. 178: 78–89.CrossRefGoogle Scholar
  12. Morales, A., Condra, M. S., Owen, J. E., Fenemore, J., and Surridge D. H. (1988). Oral and transcutaneous pharmacologic agents in the treatment of impotence.Urol. Clin. N. Am. 15: 87–93.Google Scholar
  13. Morales, A., Condra, M., Owen, J. A., Surridge, D. H., Fenemore, J., and Harris, C. (1987). Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial.J. Urol. 137: 1168–1172.PubMedGoogle Scholar
  14. Morales, A., Surridge, D. H. C., Marshall, P. G., and Fenemore, J. (1982). Nonhormonal pharmacological treatment of organic impotence.J. Urol. 128: 45–47.PubMedGoogle Scholar
  15. Peters, R. H., Koch P. C., and Blythe, B. L. (1988). Differential effects of yohimbine and naloxone on copulatory behaviors of male rats.Behav. Neurosci. 102: 559–564.PubMedCrossRefGoogle Scholar
  16. Rechtschaffen, A., and Kales, A. (1968).A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects, Public Health Service, U.S. Government Printing Office, Washington, DC.Google Scholar
  17. Reid, K., Morales, A., Harris, C., Surridge, D. H. C., Condra, M., and Owen, J. (1987). Double-blind trial of yohimbine in treatment of psychogenic impotence.Lancet 1, 421–423.CrossRefGoogle Scholar
  18. Reynolds, C. F., Frank, E., Thase, M. E., Houck, P. R., Jennings, J. R., Howell, J. R., Lilienfeld, S. O., and Kupfer, D. J. (1988). Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a brief sexual function questionnaire for men.Psychiat. Res. 24: 231–250.CrossRefGoogle Scholar
  19. Riley, A. J., Goodman, R. E., Kellett, J. M., and Orr, R. (1989). Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy.Sex. Marital Ther. 4: 17–26.Google Scholar
  20. Rosen, R. C., and Ashton, A. K. (1993). Prosexual drugs: Empirical status of the “New Aphrodisiacs.”Arch. Sex. Behav. 22: 521–543.PubMedCrossRefGoogle Scholar
  21. Schiavi, R. C. (1988). Nocturnal penile tumescence in the evaluation of erectile disorders: A critical review.J. Sex Marital Ther. 14: 83–95.PubMedGoogle Scholar
  22. Segraves, R. T. (1989). Effects of psychotropic drugs on human erection and ejaculation.Arch. Gen. Psychiat. 46: 275–284.PubMedGoogle Scholar
  23. Smith, E. R., and Davidson, J. M. (1990). Yohimbine attenuates aging-induced sexual deficiencies in male rats.Physiol. Behav. 47: 631–641.PubMedCrossRefGoogle Scholar
  24. Smith, E. R., Lee, R. L., Schnur, S. L., and Davidson, J. M. (1987). Alpha 2-adrenoceptor antagonists and male sexual behavior: I. Mating behavior.Physiol. Behav. 41: 7–14.PubMedCrossRefGoogle Scholar
  25. Sohn, M. H., Seeger, U., Sikora, R., and Jakse, G. (1993). Criteria for examiner-independent nocturnal penile tumescence and rigidity monitoring (NPTR): Correlations to invasive diagnostic methods.Int. J. Impotence Res. 5: 59–68.Google Scholar
  26. Sonda, L. P., Mazo, R., and Chancellor, M. B. (1990). The role of yohimbine for the treatment of erectile impotence.J. Sex Marital Ther. 16: 15–21.PubMedGoogle Scholar
  27. Steiger, A., and Benkert, O. (1989). Examination and treatment of sleep-related painful erections—A case report.Arch. Sex. Behav. 18: 263–267.PubMedCrossRefGoogle Scholar
  28. Steiger, A., Holsboer, F., and Benkert, O. (1987). Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers.Psychopharmacology 92: 110–114.PubMedCrossRefGoogle Scholar
  29. Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. (1989). Effect of yohimbine hydrochloride on erectile impotence: A double-blind study.J. Urol. 141: 1360–1363.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Klaus Mann
    • 1
  • Thomas Klingler
    • 1
  • Susanne Noe
    • 1
  • Joachim Röschke
    • 1
  • Stefan Müller
    • 2
  • Otto Benkert
    • 1
  1. 1.Department of PsychiatryUniversity of MainzMainzGermany
  2. 2.Department of UrologyUniversity of MainzMainzGermany

Personalised recommendations